Drug Profile
Adefovir dipivoxil
Alternative Names: Adesera; Bis-POM PMEA; GS 0840; GS 840; Hepsera; Piv2PMEALatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
- Developer Columbia University; Gilead Sciences; Institute of Organic Chemistry and Biochemistry (Prague)
- Class Analgesics; Anti-inflammatories; Antiretrovirals; Phosphonic acids; Purine nucleotides; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors; Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B
- Discontinued HIV infections; Rheumatic disorders
Most Recent Events
- 06 Jan 2020 No development reported - Phase-I/II for Hepatitis B (Combination therapy, Prevention) in USA (PO)
- 27 Feb 2017 Gilead Sciences has patent protection for Adefovir dipivoxil in Europe and USA (Gilead Sciences 10-K, February 2017)
- 01 Sep 2012 Gilead Sciences completes a phase I/II trial in Hepatitis B (Prevention, Combination therapy) in USA (PO) (NCT01146808)